Kim M. Smits

3.2k citations

37 papers · 1.7k indexed · 1 hit paper · h-index 22

Molecular Biology top 10%
Pulmonary and Respiratory Medicine top 5%
Cancer Research top 5%
Oncology top 10%
Pathology and Forensic Medicine top 10%

Co-authors: Manon van Engeland James G. Herman Veerle Melotte Alexander Koch Sophie C. Joosten Wim Van Criekinge Leander Van Neste Muriel X.G. Draht
Topics: Epigenetics and DNA Methylation (17 papers)Renal cell carcinoma treatment (8 papers)Neurotransmitter Receptor Influence on Behavior (5 papers)
Cited by: Cancer Research Biological Psychiatry Molecular Biology
Journals: Journal of Clinical OncologySHILAP Revista de lepidopterologíaClinical Cancer Research
Partner nations: Netherlands United States Belgium

In The Last Decade

Kim M. Smits

36 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Analysis of DNA methylation in cancer: location revisited

2018 491 citations Alexander Koch, Sophie C. Joosten et al. profile →

Peers

Countries citing papers authored by Kim M. Smits

Since Specialization

Citations

This map shows the geographic impact of Kim M. Smits's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kim M. Smits with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kim M. Smits more than expected).

Fields of papers citing papers by Kim M. Smits

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kim M. Smits. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kim M. Smits. The network helps show where Kim M. Smits may publish in the future.

Co-authorship network of co-authors of Kim M. Smits

This figure shows the co-authorship network connecting the top 25 collaborators of Kim M. Smits. A scholar is included among the top collaborators of Kim M. Smits based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kim M. Smits. Kim M. Smits is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	OTP, CD44, and Ki-67: A Prognostic Marker Panel for Relapse-Free Survival in Patients with Surgically Resected Pulmonary Carcinoid 2024 ·Modern Pathology ·Laura Moonen,Jules L. Derks,Michael A. den Bakker,Lisa M. Hillen,Robert Jan van Suylen,Jan H. von der Thüsen,(unknown),(unknown),Ronald Damhuis,Kim M. Smits,Esther C. van den Broek,Wieneke A. Buikhuisen,Anne‐Marie C. Dingemans,Ernst‐Jan M. Speel	3
2	Histologic re‑evaluation of a population‑based series of renal cell carcinomas from The Netherlands Cohort Study according to the 2022 ISUP/WHO classification 2023 ·Oncology Letters ·(unknown),Iryna Samarska,Andrés Matoso,(unknown),Marcella Baldewijns,Christina Hulsbergen‐van de Kaa,(unknown),Guido M.J.M. Roemen,(unknown),Manon van Engeland,Axel zur Hausen,Leo J. Schouten,Kim M. Smits	5
3	Technical considerations in PCR-based assay design for diagnostic DNA methylation cancer biomarkers 2022 ·Clinical Epigenetics ·(unknown),(unknown),Kristien Wouters,Johan Vandersmissen,Wim Van Criekinge,James G. Herman,Veerle Melotte,Leo J. Schouten,Manon van Engeland,Kim M. Smits	9
4	Identification of DNA methylation markers for early detection of CRC indicates a role for nervous system-related genes in CRC 2021 ·Clinical Epigenetics ·(unknown),(unknown),Alexander Koch,Muriel X.G. Draht,(unknown),Kristien Wouters,Nathalie Vaes,Tim De Meyer,Beatriz Carvalho,Gerrit A. Meijer,James G. Herman,Kim M. Smits,Manon van Engeland,Veerle Melotte	25
5	Diagnostic DNA Methylation Biomarkers for Renal Cell Carcinoma: A Systematic Review 2019 ·European Urology Oncology ·(unknown),Nathalie Vaes,Maureen J.B. Aarts,Joep G.H. van Roermund,Leo J. Schouten,Egbert Oosterwijk,Veerle Melotte,Vivianne C. G. Tjan‐Heijnen,Manon van Engeland,Kim M. Smits	18
6	Prognostic DNA methylation markers for sporadic colorectal cancer: a systematic review 2018 ·Clinical Epigenetics ·Muriel X.G. Draht,(unknown),Alexander Koch,Heike I. Grabsch,Matty P. Weijenberg,Manon van Engeland,Veerle Melotte,Kim M. Smits	34
7	Epigenetics in renal cell cancer: mechanisms and clinical applications 2018 ·Nature Reviews Urology ·Sophie C. Joosten,Kim M. Smits,Maureen J.B. Aarts,Veerle Melotte,Alexander Koch,Vivianne C. G. Tjan‐Heijnen,Manon van Engeland	114
8	A Four-Gene Promoter Methylation Marker Panel Consisting of GREM1, NEURL, LAD1, and NEFH Predicts Survival of Clear Cell Renal Cell Cancer Patients 2016 ·Clinical Cancer Research ·Iris J.H. van Vlodrop,Sophie C. Joosten,Tim De Meyer,Kim M. Smits,Leander Van Neste,Veerle Melotte,Marcella Baldewijns,Leo J. Schouten,Piet A. van den Brandt,Jana Jeschke,Joo Mi Yi,Kornel E. Schuebel,Nita Ahuja,James G. Herman,Maureen J.B. Aarts,Fred T. Bosman,Wim Van Criekinge,Manon van Engeland	44
9	CHFR Promoter Methylation Indicates Poor Prognosis in Stage II Microsatellite Stable Colorectal Cancer 2014 ·Clinical Cancer Research ·Arjen H.G. Cleven,Sarah Derks,Muriel X.G. Draht,Kim M. Smits,Veerle Melotte,Leander Van Neste,(unknown),Valérie Jooste,Caroline Chapusot,Matty P. Weijenberg,James G. Herman,Adriaan P. de Bruı̈ne,Manon van Engeland	30
10	Spectrin Repeat Containing Nuclear Envelope 1 and Forkhead Box Protein E1 Are Promising Markers for the Detection of Colorectal Cancer in Blood 2014 ·Cancer Prevention Research ·Veerle Melotte,Joo Mi Yi,Marjolein H.F.M. Lentjes,Kim M. Smits,Leander Van Neste,Hanneke E.C. Niessen,Kristien Wouters,Joost Louwagie,Kornel E. Schuebel,James G. Herman,Stephen B. Baylin,Wim Van Criekinge,Gerrit A. Meijer,Nita Ahuja,Manon van Engeland	31
11	Cardiac comorbidity is an independent risk factor for radiation-induced lung toxicity in lung cancer patients 2013 ·Radiotherapy and Oncology ·Georgi Nalbantov,Bas Kietselaer,Katrien Vandecasteele,Cary Oberije,Maaike Berbée,Esther G.C. Troost,Anne‐Marie C. Dingemans,Angela van Baardwijk,Kim M. Smits,André Dekker,Johan Bussink,Dirk De Ruysscher,Yolande Lievens,Philippe Lambin	47
12	Emerging evidence for CHFR as a cancer biomarker: from tumor biology to precision medicine 2013 ·Cancer and Metastasis Reviews ·Sarah Derks,Arjen H.G. Cleven,Veerle Melotte,Kim M. Smits,Johann C. Brandes,Nilofer S. Azad,Wim Van Criekinge,Adriaan P. de Bruı̈ne,James G. Herman,Manon van Engeland	35
13	Modified UroVysion scoring criteria increase the urothelial carcinoma detection rate in cases of equivocal urinary cytology 2011 ·Histopathology ·Clément J.R. Huysentruyt,Marcella Baldewijns,(unknown),(unknown),(unknown),Kim M. Smits,C. van de Beek,Ernst‐Jan M. Speel	7
14	Loss of SerpinA5 protein expression is associated with advanced-stage serous ovarian tumors 2010 ·Modern Pathology ·(unknown),Kim M. Smits,Pauline de Graeff,G. Bea A. Wisman,Ate G.J. van der Zee,B.F.M. Slangen,Adriaan P. de Bruı̈ne,Manon van Engeland,Nathalie L.G. Sieben,Koen Van de Vijver	28
15	Body Mass Index and von Hippel-Lindau Gene Mutations in Clear-cell Renal Cancer: Results of the Netherlands Cohort Study on Diet and Cancer 2010 ·Annals of Epidemiology ·Kim M. Smits,Leo J. Schouten,(unknown),Bas A.J. Verhage,Boukje A. C. van Dijk,Christina A. Hulsbergen‐van de Kaa,R. Alexandra Goldbohm,Egbert Oosterwijk,Piet A. van den Brandt	8
16	Prognostic Significance of Gremlin1 (GREM1) Promoter CpG Island Hypermethylation in Clear Cell Renal Cell Carcinoma 2009 ·American Journal Of Pathology ·Iris J.H. van Vlodrop,Marcella Baldewijns,Kim M. Smits,Leo J. Schouten,Leander Van Neste,Wim Van Criekinge,Hendrik Van Poppel,Evelyne Lerut,Kornel E. Schuebel,Nita Ahuja,James G. Herman,Adriaan P. de Bruı̈ne,Manon van Engeland	67
17	The influence of 5-HTTLPR and STin2 polymorphisms in the serotonin transporter gene on treatment effect of selective serotonin reuptake inhibitors in depressive patients 2008 ·Psychiatric Genetics ·Kim M. Smits,Luc Smits,Frenk Peeters,Jan Schouten,Rob Janssen,Hubert J.M. Smeets,Jim van Os,Martin H. Prins	44
18	Serotonin transporter polymorphisms and the occurrence of adverse events during treatment with selective serotonin reuptake inhibitors 2007 ·International Clinical Psychopharmacology ·Kim M. Smits,Luc Smits,Frenk Peeters,Jan Schouten,Rob Janssen,Hubert J.M. Smeets,Jim van Os,Martin H. Prins	48
19	A review on the design and reporting of studies on drug–gene interaction 2005 ·Journal of Clinical Epidemiology ·Kim M. Smits,Jan Schouten,Luc Smits,Foekje F. Stelma,Patty J. Nelemans,Martin H. Prins	21
20	Influence of SERTPR and STin2 in the serotonin transporter gene on the effect of selective serotonin reuptake inhibitors in depression: a systematic review 2004 ·Molecular Psychiatry ·Kim M. Smits,Luc Smits,Jan Schouten,Foekje F. Stelma,Patricia J. Nelemans,Martin H. Prins	137

About Kim M. Smits

Kim M. Smits is a scholar working on Biological Psychiatry, Cancer Research and Pulmonary and Respiratory Medicine, having authored 37 papers that have together received 1.7k indexed citations. Recurring topics across this work include Epigenetics and DNA Methylation (17 papers), Renal cell carcinoma treatment (8 papers) and Neurotransmitter Receptor Influence on Behavior (5 papers). The work is most often cited by research in Cancer Research (430 citations), Biological Psychiatry (54 citations) and Molecular Biology (1.1k citations). Kim M. Smits has collaborated with scholars based in Netherlands, United States and Belgium. Frequent co-authors include Manon van Engeland, James G. Herman, Veerle Melotte, Alexander Koch, Sophie C. Joosten, Wim Van Criekinge, Leander Van Neste, Muriel X.G. Draht, Martin H. Prins and Luc Smits. Their work appears in journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact